AstraZeneca wins FDA nod for Imfinzi and a new rare disease drug, expanding bladder cancer treatment and rare disease care.
Lilly and Stipple Bio have partnered to advance targeted cancer treatment through tumour-specific technology.
Biocon has secured another milestone in the US cancer biosimilar market with FDA approval for Pebrilzo (pertuzumab-qcay), its biosimilar version of Roche’s Perjeta.
Natco Pharma is expanding its oncology drug pipeline with three new launches to offset declining Revlimid sales and restore revenue growth.
Delhi air pollution health risks extend beyond respiratory illness, with prolonged PM2.5 exposure linked to cardiovascular and kidney complications.
Sun Pharma's USD 11.75 billion Organon acquisition involves a USD 4 billion syndicated loan to refinance bridge financing, alongside other funding options to manage acquisition debt and maintain financial flexibility.
Indian homes have always been about art, spirituality, and celebration. You've got your entrance decorated with flowers and diyas, and you've got your prayer room with the idols and all that sort of thing.
Mankind Pharma's ensartinib deal brings Betta Pharmaceuticals' targeted lung cancer treatment closer to the Indian oncology market.
India's first Zika vaccine has moved a step closer to human testing, marking an important development in the country's efforts to strengthen protection against emerging mosquito-borne infections.
Summit Therapeutics' ivonescimab has encountered a regulatory challenge after the US Food and Drug Administration (FDA) declined to approve the investigational lung cancer treatment.